Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Peptide Analogs
A tetrasubstituted 29-residue synthetic peptide corresponding to the N-terminal GRF(1-29) sequence, bearing a C-terminal albumin-binding side chain.
Reviewed by Dr. James Whitfield, PharmD · Published · Last reviewed · For research use only.
Type
Synthetic peptide (acylated, 29 residues)
Molecular formula
C165H269N47O46
Molecular weight
~3,647 g/mol
CAS number
446262-90-4 (with DAC); 863288-34-0 (no-DAC)
Amino acids
29
Modification
Tetrasubstituted GRF(1-29) with a C-terminal Lys-linked maleimidopropionyl albumin-binding group (DAC); C-terminal amide.
A 29-residue synthetic peptide corresponding to the N-terminal GRF(1-29) sequence of a 44-residue hypothalamic peptide. Cryo-EM studies of GRF(1-29)-class peptides bound to a class B GPCR-Gs complex resolve a continuous a-helical conformation in which the N-terminal segment inserts into the receptor transmembrane bundle and the central segment contacts the extracellular domain. Four amino-acid substitutions confer resistance to dipeptidyl-peptidase proteolysis; a C-terminal Lys-linked maleimidopropionyl (DAC) side chain reacts with serum albumin to confer reversible binding, extending circulatory half-life. A no-DAC variant (Mod GRF 1-29; ~3,368 g/mol; PubChem CID 91976842) is also offered.
Lyophilized
20°C
typically stable 24-36 months desiccated and protected from light.
Avoid freeze-thaw; aliquot; protect from light and moisture. The DAC maleimide group is thiol-reactive.
Reviews
Memdouh S, et al. (2021). Drug Test Anal
Halmos G, et al. (2025). Rev Endocr Metab Disord
Halmos G, et al. (2023). Vitam Horm
Reviews
Montero-Hidalgo AJ, et al. (2025). Rev Endocr Metab Disord
Dieguez C, et al. (2025). Rev Endocr Metab Disord
Schally AV, et al. (2024). Rev Endocr Metab Disord
Müller EE, et al. (1999). Physiol Rev
Clinical
Teichman SL, et al. (2006). J Clin Endocrinol Metab
Ionescu M, Frohman LA. (2006). J Clin Endocrinol Metab
Stanley TL, et al. (2011). J Clin Endocrinol Metab
Primary research
Timms M, et al. (2019). Drug Test Anal
Timms M, et al. (2019). Drug Test Anal
Henninge J, et al. (2010). Drug Test Anal
Sackmann-Sala L, et al. (2009). Growth Horm IGF Res
Alba M, et al. (2006). Am J Physiol Endocrinol Metab
Jetté L, et al. (2005). Endocrinology
Alba M, et al. (2005). Endocrinology
Bongers J, et al. (1992). Biochim Biophys Acta
Kato M, Sakuma Y. (1997). Endocrinology
Zhou F, et al. (2020). Nat Commun
Thomas A, et al. (2012). Methods
Thomas A, et al. (2024). J Mass Spectrom
Uçaktürk E, Nemutlu E. (2026). J Pharm Biomed Anal
Also known as: CJC-1295 with DAC, DAC:GRF, Mod GRF 1-29 (no-DAC variant)
Research Use Only
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
| Compound | Type | Molecular weight | CAS number |
|---|---|---|---|
| CJC-1295This page | Synthetic peptide (acylated, 29 residues) | ~3,647 g/mol | 446262-90-4 (with DAC); 863288-34-0 (no-DAC) |
| LUV RT | Synthetic peptide (acylated, 39 residues) | ~4,731 Da | 2381089-83-2 |
| LUV SM | Synthetic peptide (acylated, 31 residues) | ~4,114 g/mol | 910463-68-2 |
| LUV TRZ2 | Synthetic linear peptide (acylated, 39 residues) | ~4,814 g/mol | 2023788-19-2 |
| AOD-9604 | Synthetic peptide (cyclic, 16 residues) | ~1,815 g/mol | 221231-10-3 |
Comparison of laboratory reference specifications only. For research use only; not a therapeutic comparison.
Quality & methods